155 related articles for article (PubMed ID: 26376154)
21. Sustained expression of nucleophosmin (NPM1) mutation at late relapse presenting as isolated myeloid sarcoma in a patient with acute myeloid leukemia.
Scholl S; Lüftner J; Mügge LO; Schmidt V; Fricke HJ; Höffken K
Ann Hematol; 2007 Oct; 86(10):763-5. PubMed ID: 17639390
[No Abstract] [Full Text] [Related]
22. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
23. [Analysis of the effect of rubomycin in cell cultures from patients with acute leukemia].
Gerasimova NA; Korenevskaia MI; Dul'tsina SM; Kovaleva LG; Terent'eva EI
Lab Delo; 1971; 10():605-8. PubMed ID: 4114120
[No Abstract] [Full Text] [Related]
24. [Rubidomycin-daunomycin therapy in acute myeloblastic leukemia].
Dano K; Nissen NI; Pedersen-Bjergaard J; Thiede T
Nord Med; 1968 Oct; 80(44):1475-82. PubMed ID: 5247180
[No Abstract] [Full Text] [Related]
25. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
[TBL] [Abstract][Full Text] [Related]
26. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels.
Hatfield KJ; Hovland R; Øyan AM; Kalland KH; Ryningen A; Gjertsen BT; Bruserud Ø
Leukemia; 2008 Feb; 22(2):287-93. PubMed ID: 17943167
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
28. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?
Pasqualucci L; Li S; Meloni G; Schnittger S; Gattenlohner S; Liso A; Di Ianni M; Martelli MP; Pescarmona E; Foa R; Haferlach T; Skoda RC; Falini B
Leukemia; 2008 Jul; 22(7):1459-63. PubMed ID: 18200037
[No Abstract] [Full Text] [Related]
29. Acute myeloid leukemia with mutated nucleophosmin (NPM1): molecular, pathological, and clinical features.
Falini B
Cancer Treat Res; 2010; 145():149-68. PubMed ID: 20306250
[TBL] [Abstract][Full Text] [Related]
30. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 2-2005. A 39-year-old woman with headache, stiff neck, and photophobia.
Ballen KK; Hasserjian RP
N Engl J Med; 2005 Jan; 352(3):274-83. PubMed ID: 15659728
[No Abstract] [Full Text] [Related]
31. Two novel NPM1 mutations in a therapy-responder AML patient.
Pianta A; Fabbro D; Damiani D; Tiribelli M; Fanin R; Franzoni A; Romanello M; Tell G; Di Loreto C; Damante G
Hematol Oncol; 2010 Sep; 28(3):151-5. PubMed ID: 19593743
[TBL] [Abstract][Full Text] [Related]
32. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
[TBL] [Abstract][Full Text] [Related]
33. Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib.
Georgiou G; Efthymiou A; Vardounioti I; Boutsikas G; Angelopoulou MK; Vassilakopoulos TP; Kyrtsonis MC; Plata E; Tofas P; Bitsani A; Bartzi V; Pessach I; Dimou M; Panayiotidis P
Leukemia; 2012 Apr; 26(4):824-6. PubMed ID: 21986839
[No Abstract] [Full Text] [Related]
34. Simultaneous occurrence of acute myeloid leukaemia with mutated nucleophosmin (NPM1) in the same family.
Cazzaniga G; Lo Nigro L; Cifola I; Milone G; Schnittger S; Haferlach T; Mirabile E; Costantino F; Martelli MP; Mastrodicasa E; Di Raimondo F; Aversa F; Biondi A; Falini B
Leukemia; 2009 Jan; 23(1):199-203. PubMed ID: 18596743
[No Abstract] [Full Text] [Related]
35. Therapy-related acute myeloid leukaemia with mutated NPM1: treatment induced or de novo in origin?
Falini B
Leukemia; 2008 May; 22(5):891-2. PubMed ID: 18478020
[No Abstract] [Full Text] [Related]
36. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
Bains A; Luthra R; Medeiros LJ; Zuo Z
Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of MEIS1 impairs long-term expansion of CD34+ NPM1-mutated acute myeloid leukemia cells.
Woolthuis CM; Han L; Verkaik-Schakel RN; van Gosliga D; Kluin PM; Vellenga E; Schuringa JJ; Huls G
Leukemia; 2012 Apr; 26(4):848-53. PubMed ID: 21986840
[No Abstract] [Full Text] [Related]
38. Is the association of "cup-like" nuclei with mutation of the NPM1 gene in acute myeloid leukemia clinically useful?
Bennett JM; Pryor J; Laughlin TS; Rothberg PG; Burack WR
Am J Clin Pathol; 2010 Oct; 134(4):648-52. PubMed ID: 20855646
[TBL] [Abstract][Full Text] [Related]
39. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice.
Falini B; Martelli MP; Mecucci C; Liso A; Bolli N; Bigerna B; Pucciarini A; Pileri S; Meloni G; Martelli MF; Haferlach T; Schnittger S
Haematologica; 2008 May; 93(5):775-9. PubMed ID: 18367491
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
Dvorakova D; Racil Z; Jeziskova I; Palasek I; Protivankova M; Lengerova M; Razga F; Mayer J
Am J Hematol; 2010 Dec; 85(12):926-9. PubMed ID: 20981679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
